UK-based graphene developer Haydale announced its unaudited interim results for the six months ended 31 December 2022 (H1 FY2023). Revenues were £1.78 million (up 50% from H1 FY2022), and operating loss was £1.89 million (up from £1.75 million in 2022). At the end of the year, Haydale had £2.97 million, following a successful fund raise of £5.14 million in September 2022.
The updates that it is starting to sell its biomedical inks in Europe, with advanced trials being conducted by several parties which include electronic blood glucose reader compatibility tests.
The company also updates that it shipped one ton of its functionalised graphene powder to cycle tyre manufacturer Vittoria Spa, with more orders anticipated. Haydale also says it has developed a prototype underfloor heating solution with the potential to replace higher voltage electric or water based floor heating systems in residential buildings.
Disclosure: the author of this post holds shares at Haydale